» Articles » PMID: 9539782

Detection and Characterization of Carcinoma Cells in the Blood

Overview
Specialty Science
Date 1998 May 16
PMID 9539782
Citations 222
Authors
Affiliations
Soon will be listed here.
Abstract

A highly sensitive assay combining immunomagnetic enrichment with multiparameter flow cytometric and immunocytochemical analysis has been developed to detect, enumerate, and characterize carcinoma cells in the blood. The assay can detect one epithelial cell or less in 1 ml of blood. Peripheral blood (10-20 ml) from 30 patients with carcinoma of the breast, from 3 patients with prostate cancer, and from 13 controls was examined by flow cytometry for the presence of circulating epithelial cells defined as nucleic acid+, CD45(-), and cytokeratin+. Highly significant differences in the number of circulating epithelial cells were found between normal controls and patients with cancer including 17 with organ-confined disease. To determine whether the circulating epithelial cells in the cancer patients were neoplastic cells, cytospin preparations were made after immunomagnetic enrichment and were analyzed. Epithelial cells from patients with breast cancer generally stained with mAbs against cytokeratin and 3 of 5 for mucin-1. In contrast, no cells that stained for these antigens were observed in the blood from normal controls. The morphology of the stained cells was consistent with that of neoplastic cells. Of 8 patients with breast cancer followed for 1-10 months, there was a good correlation between changes in the level of tumor cells in the blood with both treatment with chemotherapy and clinical status. The present assay may be helpful in early detection, in monitoring disease, and in prognostication.

Citing Articles

Current status and new directions for hepatocellular carcinoma diagnosis.

Tu J, Wang B, Wang X, Huo K, Hu W, Zhang R Liver Res. 2025; 8(4):218-236.

PMID: 39958920 PMC: 11771281. DOI: 10.1016/j.livres.2024.12.001.


Detection and Characterization of Circulating Tumor Cells in Colorectal Cancer Patients via Epithelial-Mesenchymal Transition Markers.

Takahashi Y, Ijiri Y, Fujino S, Elnaz N, Kishimoto A, Shirai K Cancers (Basel). 2025; 17(2).

PMID: 39858085 PMC: 11763958. DOI: 10.3390/cancers17020303.


Silica-coated magnetic nanobeads in a flow enrichment target capture Halbach (FETCH) magnetic separation system for circulating tumor cell enrichment.

Liu P, He S, Mentink A, Hart P, Wu Y, Terstappen L FEBS Lett. 2025; 599(5):724-738.

PMID: 39743435 PMC: 11891416. DOI: 10.1002/1873-3468.15094.


Potential role of circulating tumor cells and cell-free DNA as biomarkers in oral squamous cell carcinoma: A prospective single-center study.

Eboshida N, Hamada A, Higaki M, Obayashi F, Ito N, Yamasaki S PLoS One. 2024; 19(12):e0309178.

PMID: 39729421 PMC: 11676868. DOI: 10.1371/journal.pone.0309178.


Liquid biopsy in cancer current: status, challenges and future prospects.

Ma L, Guo H, Zhao Y, Liu Z, Wang C, Bu J Signal Transduct Target Ther. 2024; 9(1):336.

PMID: 39617822 PMC: 11609310. DOI: 10.1038/s41392-024-02021-w.


References
1.
Herlyn D, Herlyn M, Ross A, Ernst C, Atkinson B, KOPROWSKI H . Efficient selection of human tumor growth-inhibiting monoclonal antibodies. J Immunol Methods. 1984; 73(1):157-67. DOI: 10.1016/0022-1759(84)90041-3. View

2.
Ghossein R, Rosai J . Polymerase chain reaction in the detection of micrometastases and circulating tumor cells. Cancer. 1996; 78(1):10-6. DOI: 10.1002/(SICI)1097-0142(19960701)78:1<10::AID-CNCR3>3.0.CO;2-L. View

3.
Shaw H, Beattie C, McCarthy W, Milton G . Late relapse from cutaneous stage I malignant melanoma. Arch Surg. 1985; 120(10):1155-9. DOI: 10.1001/archsurg.1985.01390340053010. View

4.
Pantel K, Riethmuller G . Micrometastasis detection and treatment with monoclonal antibodies. Curr Top Microbiol Immunol. 1996; 213 ( Pt 3):1-18. DOI: 10.1007/978-3-642-80071-9_1. View

5.
Corey E, Arfman E, Oswin M, Melchior S, Tindall D, Young C . Detection of circulating prostate cells by reverse transcriptase-polymerase chain reaction of human glandular kallikrein (hK2) and prostate-specific antigen (PSA) messages. Urology. 1997; 50(2):184-8. DOI: 10.1016/S0090-4295(97)00262-8. View